How Children's Bowel Disease Responds After Switching IBD Medications
Part of Digestive system, Skin clinical trials.
This study follows children who had to stop one type of IBD medicine (anti-TNFα) because it caused a skin condition called psoriasis, and were switched to a different medicine called ustekinumab. Researchers want to see how well their bowel disease is controlled with the new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 19 years old
- You have been diagnosed with Crohn's disease or ulcerative colitis (inflammatory bowel disease)
- You took an anti-TNFα medication for your IBD for at least 3 months
- You developed severe psoriasis (a skin condition) from the anti-TNFα that didn't improve with skin creams or other treatments, and a skin doctor confirmed this
- You have now switched to ustekinumab as your new IBD medication
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study tests whether a biologic therapy can help children with inflammatory bowel disease (IBD) when their disease is severe or when they're having a flare-up. The goal is to see if this treatment can reduce symptoms and improve their quality of life.
This study monitors levels of certain medications (infliximab, adalimumab, vedolizumab, ustekinumab) in children with inflammatory bowel disease to see if adjusting the dose helps them feel better. It aims to improve treatment outcomes.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Hear when a new Chronic Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.